Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Aging Media Network Announces 2023 Aspect Awards Winners


News Image

Aging Media Network (AMN) is proud to announce the winners of the 2023 Aspect Awards. With 53 submissions in the categories of Home Health & Home Care, Hospice & Palliative Care, Senior Housing & Senior Living, Skilled Nursing (SNF), and Behavioral Health, the scope of creativity is broader than ever before.

The program was judged by 10 individuals from across the care continuum, with expertise in sales, marketing and public relations. Entries were evaluated based on creativity, style and impact, quality, and goals and results. Each industry/category received first, second and third place decisions, classified by entries submitted among either vendors or providers.

“Creating great advertising and marketing campaigns to raise both awareness and differentiation will be critical for the entire healthcare industry to grow,” said George Yedinak, Executive Vice President of Aging Media Network. “This year’s Aspect Awards entries showcase the strategic and creative driving forces behind this movement.”

Participation from national, regional and local companies, as well as an array of creative agencies, makes the Aspect Awards a powerful benchmark for longevity marketing and creative strategy in 2023.

Introducing the 2023 Winners in alphabetical order, sorted by industry and category:

BEHAVIORAL HEALTH

Multimedia Campaign

Provider

Winner: Avera Health

Rebranding

Vendor

Winner: Dreamscape Marketing    

HOME HEALTH & HOME CARE

Audio / Radio / Podcast Campaign

Provider

Winner: Healing Hands Healthcare

Digital Display / PPC Campaign

Provider

Winner: Help at Home

Vendor

Winner: GA Creative on behalf of Providence

Multimedia Campaign

Provider

Winner: Sonas Home Healthcare & The Symphony Agency

Second Place: Avera Health

Third Place: Innovive Health

Print / Direct Mail / Billboard Campaign

Provider

Winner: Faith Home Healthcare

Rebranding

Provider

Winner: VNS Health

Second Place: FirstLight Home Care

Vendor

Winner: WellSky

Second Place: CHAP Inc

Social Media Campaign

Vendor

Winner: Forcura

Video / TV Campaign

Vendor

Winner: CHAP Inc

Second Place: CHAP Inc

HOSPICE & PALLIATIVE CARE

Multimedia Campaign

Provider

Winner: VITAS Healthcare

Second Place: St. Croix Hospice

New Brand Launch

Provider

Winner: Centrica Care Navigators

Second Place: Goldencare Hospice and Palliative Care LLC

Print, Direct Mail & Billboard Campaign

Vendor

Winner: Partner Plus Media/HPH Hospice, a Chapters Health Affiliate

Rebranding

Vendor

Winner: Maxwell Healthcare Associates

Video / TV Campaign

Provider

Winner: VITAS Healthcare

SENIOR HOUSING & SENIOR LIVING

Audio / Radio / Podcast Campaign

Provider

Winner: Priority Life Care / Her Stories

Second Place: Arrow Senior Living Management

Multimedia Campaign

Provider

Winner: Ohio Living

Second Place: Optima Living

Third Place: Optima Living

Vendor

Winner: Spark + Buzz Communications – Wilshire Finance Company

New Brand Launch

Provider

Winner: Arrow Senior Living Management

Second Place: Monark Grove / Beztak

Third Place: The Claiborne

Vendor

Winner: The Senior Team, Inc

Print, Direct Mail & Billboard Campaign

Provider

Winner: Christian Living Communities

Second Place: Friendship Village

Rebranding

Provider

Winner: Covenant Living Communities and Services

Second Place: Arrow Senior Living Management

Social Media Campaign

Provider

Winner: Arrow Senior Living Management

Video / TV Campaign

Provider

Winner: Arrow Senior Living Management

Second Place: Optima Living

Third Place: Holbrook Life

SKILLED NURSING (SNF)

Rebranding

Provider

Winner: Powerback Rehabilitation

Social Media Campaign

Provider

Winner: EmpowerMe Wellness

Second Place: Majestic Care

Vendor

Winner: GA Creative on behalf of Providence

Video / TV Campaign

Provider

Winner: Accolade Healthcare

About Aging Media Network

Aging Media Network is an innovative publishing company based in Chicago, Illinois, and is the publisher of Senior Housing News, Home Health Care News, Hospice News, Skilled Nursing News, and Behavioral Health Business.

Share article on social media or email:

CMI Media Group Appointed by Two Top US Pharmaceutical Companies as Omnichannel DTC & HCP Media Planning and Buying AOR


“The pitches we’ve been involved in are with highly competitive, exciting clients. What put us in the winner’s seat is our ability to work in very precise marketing,” said Joe Warren, EVP, Growth.

CMI Media Group, a leading global healthcare media strategy, planning, innovation and buying agency and part of WPP (NYSE: WPP), announced it has been chosen by two top global pharmaceutical companies as Agency of Record, with a focus on providing audience-led, insights-driven DTC and HCP media, omni-channel and analytics services. In both assignments, CMI Media Group will handle the companies’ US DTC and HCP omnichannel media planning and buying. The agency is tasked with developing media plans targeting both doctors and patients/consumers.

CMI Media Group delivers high ROI media performance and precision solutions to clients, fueled by talent, data, technology and amplification of creative. The company’s data-focused capabilities and omnichannel approach in action – dubbed “omnidynamic” by the CMI Media Group – have led to significant growth and success. In 2021 and 2022, the organization was recognized by Adweek as one of the fastest-growing agencies in the world.

“The pitches we’ve been involved in are with highly competitive, exciting clients. What put us in the winner’s seat is our ability to work in very precise marketing,” said Joe Warren, EVP, Growth. “In healthcare, today it’s more important than ever to engage healthcare professionals and patients with the information they need where and when they want it, and we are able to deliver on those capabilities for our clients. We are breaking paradigms in how data is used.”

Two of the company’s cutting edge and proprietary technologies helped propel them to both wins. Empower ™, the company’s integrated planning platform, is the health industry’s first and only end-to-end planning platform that enables continuous and personalized “insight to action” at scale. Empower allows CMI Media Group to close the loop on integrated DTC/HCP audience planning, messaging and outreach, making every campaign more effective. The platform offers cross-audience customer universe identification, segmentation, media planning, activation, measurement and on-going people-based optimization.

In addition to Empower, CMI Media Group’s PROACT™, which stands for Personalized & Responsive Omni-Channel Automated Customer Targeted, is the first and industry-leading healthcare media orchestration and automation platform, to get from data to insights to actions immediately. PROACT is the clear market leader with more active partners than any other platform and the flexibility and history to support every omnidynamic use case.

The successes are part of a winning streak that has led the company to remarkable YOY growth.

CMI Media Group is WPP’s leading healthcare media specialist. The company has brought many firsts to healthcare marketing as the leading healthcare-focused media buying and planning resource to the world’s game changers in pharma and life sciences.

Those looking to join the CMI Media Group team can visit the company’s career page for more information and a link to apply: https://cmimediagroup.com/careers/

About CMI Media Group

CMI Media Group, a WPP company (NYSE: WPP, http://www.wpp.com), is a full-service global media agency focused solely on health, wellness, and pharmaceutical marketing. CMI Media Group’s core offerings include Audience Strategy, Planning, Development, and Insights; Data and Analytics; Buying and Investment; and Direct Response and Customer Experience. As the leading media resource for the world’s top healthcare companies, CMI Media Group brings together leading technology, data, and talent to deliver seamless capabilities for clients. CMI Media Group has been recognized as a leader in DE&I, talent retention and employee development as well as one of the industry’s best places to work. To apply for a position within our teams visit https://cmimediagroup.com/careers/

Share article on social media or email:

myFace is a Platinum Supporter of the 80th Annual Meeting of the American Cleft Palate Craniofacial Association (ACPA)


myFace staff at ACPA’s 2022 Annual Meeting, from left to right: Dina Zuckerberg (Director of Family Programs), Stephanie Paul (Executive Director), and Sandy Gilbert (Senior Program Director).

“ACPA’s collaboration with myFace over the past several years has proven to benefit patients and providers, which is the ultimate goal of both organizations,” said ACPA Executive Director Adam Levy, CAE.

myFace is pleased to announce that the organization will be a Platinum Supporter for The American Cleft Palate Craniofacial Association’s (ACPA) 80th Annual Meeting, taking place May 2-6 in Raleigh, NC.

ACPA is a nonprofit association of individuals and healthcare professionals who are interested in clinical care and research advancements for those affected by cleft and craniofacial conditions. The meeting will feature sessions on advances in research and clinical and team-driven care; including poster sessions, panel presentations, and study sessions.

myFace is a national nonprofit dedicated to changing the faces – and transforming the lives – of children and adults with facial differences by providing them with access to holistic comprehensive care, education, resources and support that pave the way for better outcomes. myFace accomplishes this through:

(1) Providing grants to craniofacial centers across the country that allow them to deliver medical, dental/orthodontic, and psychosocial care, regardless of patients’ ability to pay;

(2) Direct services that meet the day-to-day needs of the craniofacial community, including Virtual Support Groups for parents, prenatal parents, adults, and adolescents; complimentary stays in the myFace Family Apartments when a patient needs to receive treatment in NYC, and free Newborn Craniofacial Care Kits given to families in need by our 37 hospital partners; and

(3) Public awareness and education efforts including our Transforming Lives Webinar Series, our myFace, myStory: Voices from the Craniofacial Community monthly podcast, and our myFace Wonder Project school assemblies, which strive to raise public awareness about craniofacial differences and foster inclusion.

myFace and ACPA entered into a partnership in 2022 to best leverage the strengths of each organization in providing resources and support for families impacted by a craniofacial conditions. myFace’s support of ACPA’s Annual Meeting underscores its deep commitment to this partnership – and to the wider craniofacial community.

“myFace is delighted to be a major supporter of ACPA’s Annual Meeting – which provides tremendous value to the craniofacial community by bringing together healthcare providers from around the world to share their findings in order to elevate craniofacial care,” said myFace Executive Director, Stephanie Paul. “This is yet another way in which myFace seeks to partner with the ACPA to provide resources that will help to transform the lives of those impacted by a craniofacial difference.”

myFace has recently partnered with ACPA in several other ways as well. In early 2022, myFace provided an educational grant to ACPA to publish a stand-alone issue of ACPA’s peer-reviewed Cleft Palate Craniofacial Journal to focus attention on the psychosocial needs of our community. myFace has also been partnering with ACPA to expand the reach and impact of its signature Transforming Lives webinar series. myFace and ACPA have also begun to partner on advocacy initiatives that serve our community, such as the Ensuring Lasting Smiles Act (ELSA). This bill would close loopholes that allow insurance companies to deny medically and dentally necessary treatment and services for patients with congenital conditions by ensuring that any procedure that restores function caused by a congenital condition would be covered by insurance.

“ACPA’s collaboration with myFace over the past several years has proven to benefit patients and providers, which is the ultimate goal of both organizations,” said ACPA Executive Director Adam Levy, CAE. “In serving intersecting communities, we’re grateful not only for myFace’s support of the 2023 Annual Meeting, but for our continued partnership in delivering services and resources to patients and their families.”

ABOUT MYFACE

Almost every hour a child in the US is born with a craniofacial difference. Each year, the faces of another 100,000 individuals are disfigured through accident or disease. These individuals join a community of hundreds of thousands who will navigate a unique journey of care and support throughout their lives. myFace is there to ensure that individuals and families in the craniofacial community receive the care, tools, and information they need to successfully navigate that journey.

For more than 72 years, myFace has provided access to care to the thousands in need each year by providing grants to top-level medical institutions. We also offer direct services through support groups, newborn craniofacial care kits, and housing for families during medical visits. myFace educates the broader community through free topic-specific webinars, workshops, and online resources. We raise critical public awareness about craniofacial differences through student assemblies that promote kindness and inclusion, and through our podcast series, where individuals can share their stories, be seen and be heard. For more information, please visit myface.org.

ABOUT ACPA

The American Cleft Palate Craniofacial Association (ACPA) is an interdisciplinary nonprofit 501(c)(3) association of interested individuals and healthcare professionals who treat and/or perform research on oral cleft and craniofacial conditions. ACPA members provide quality care for their patients. Since 1943, ACPA has worked to optimize outcomes for individuals with oral cleft and craniofacial conditions through education, support, research, advocacy, and interdisciplinary team care. ACPA members represent more than 30 disciplines in more than 50 countries worldwide. ACPA also provides information to affected individuals and families and seeks to educate the public about facial differences through its ACPA Family Services program. For more information, please visit acpacares.org.

Share article on social media or email:

Synterex Granted Micro-, Small and Medium-Sized Enterprise (SME) Status by the European Medicines Agency’s SME Office


“Having SME status will allow us to partner with both new and existing customers looking to expand into the region leveraging our regulatory services, which will help us accomplish our goal of getting new medicines to as many patients as possible.”

Clinical and regulatory consulting firm Synterex, B.V., a wholly owned subsidiary of Synterex, Inc., has been granted Micro-, Small and Medium-Sized Enterprise (SME) status by the European Medicines Agency’s (EMA) SME office.

This newly granted SME status would allow Synterex access to early and frequent regulatory interactions during drug development for human and veterinary medicines. Additionally, Synterex would be eligible for other incentives such as multi-language translation of regulatory documentation required for market authorization and potential fee reductions or waivers.

“The support that the EMA provides for SMEs will greatly benefit Synterex as we continue to expand our operations across Europe,” said Synterex President Jeanette Towles. “Having SME status will allow us to partner with both new and existing customers looking to expand into the region leveraging our regulatory services, which will help us accomplish our goal of getting new medicines to as many patients as possible.”

The EMA plays a central role in facilitating the development and authorization of medicines across Europe. The SME initiative promotes innovation from smaller companies to ensure Europe continues to be a favorable environment for preclinical and clinical development of promising new therapeutic options. Detailed information on SME status can be found here.

For more information on Synterex, please visit http://www.synterex.com or join the conversation by liking and following us on the company’s social media channels: Twitter and LinkedIn.

About Synterex, Inc.:

Synterex is a WBENC-Certified Women’s Business Enterprise and disability-owned global clinical and regulatory consulting firm that provides clinical development solutions.

Delivering quality regulatory documentation requires navigating an evolving landscape influenced by regulators, research committees, healthcare professionals, and—most importantly—the scientific method itself.

At Synterex, we forge lasting and meaningful relationships that flex with the dynamic nature of science and technology.

Our staffers are seasoned and dedicated, with extensive experience doing the work hands-on as well as building and leading teams. We are committed to applying our years of experience and current subject matter and technical knowledge to help clients deliver important new therapies to patients in an expedient manner.

Share article on social media or email:



Salimetrics Launches + Stress Add-on for At-Home Sleep Testing


Sleep and Stress Test

When cortisol levels are elevated due to stress or other factors, it can interfere with the production and regulation of melatonin, the hormone responsible for promoting sleep.

Few objective measures exist on a physiological level that can be routinely implemented to reveal the exact timing of different circadian phases. However, individuals now have the flexibility to perform a home-based Sleep + Stress Assessment by including salivary cortisol, a well-known stress hormone. The + Stress add-on is available for all three (3) Circadian Phase Assessments: Dim Light Melatonin Onset (DLMO), Dim Light Melatonin Offset (DLMOff), and the 24-Hour Circadian Phase Map, providing a clearer window into each individual’s unique circadian physiology. “By measuring both cortisol and melatonin at the same time, it is possible to gain more insight into the body’s internal 24-hour “clock” that regulates many physiological processes, including sleep and wakefulness, hormone production, and metabolism,” says Steve Granger, Ph.D., Chief Scientific Officer at Salimetrics.

Measuring melatonin and cortisol levels simultaneously over multiple time points can help check for disruptions to the normal circadian rhythm, which may be indicative of certain sleep disorders, depression, or chronic stress. “While the production of melatonin is controlled by the body’s internal clock in response to light and darkness, and is highest at night to promote sleep, cortisol is released by the adrenal gland in response to stress and is typically highest in the morning and decreases throughout the day,” says Granger. “When cortisol levels are elevated due to stress or other factors, it can interfere with the production and regulation of melatonin, the hormone responsible for promoting sleep. In effect, elevated cortisol around bedtime means your body is physiologically heading in the opposite direction when you are trying to fall asleep, stay asleep, or obtain restorative sleep. Additionally, cortisol levels that are too low can also impact sleep quality. Therefore, maintaining normal cortisol levels is also important for overall sleep health.”

While melatonin testing was central to the initial circadian phase assessment, Salimetrics worked quickly to add the stress component as an optional add-on. “While we recognize the importance of the cortisol/melatonin relationship, our initial launch goal was to keep pricing as low as possible,” says Granger. “However, the potential of this relationship is often invaluable in treating sleep-related disruptions, so we worked quickly to make it available as part of our online test menu.”

Now, sleep medicine providers have a community-driven tool to aid in the management of circadian rhythm sleep-wake disorders (CRSWD) which can be utilized in two ways – firstly, to establish a baseline understanding of an individual’s physiological rhythms, and secondly, to focus on specific targets for treatment. By adopting a community-driven approach, Salimetrics is building a more comprehensive system that is better equipped to meet the diverse needs of its providers. “We’ve been committed to incorporating feedback from both the sleep medicine community and the patients themselves to continually enhance the ease and effectiveness of our sleep tests since inception,” says Granger.

Sleep health providers can visit https://biologyofsleep.com to learn more about how to integrate circadian phase assessments or to register in 5 minutes or less. Once registered, providers can immediately refer patients to order their assessment kit. From there, Salimetrics facilitates the in-between steps, until results are sent to the provider and patient through a HIPAA compliant results portal.

About Salimetrics

Salimetrics’ assay kits and CLIA-certified testing services are used to measure salivary analytes related to stress, behavior and development, inflammation, sleep, reproduction, health, and immune function. Founded in 1998 by Douglas A. Granger, Ph.D., Salimetrics, LLC supports CROs, pharmaceuticals, academic researchers, and the immunodiagnostic industry worldwide with innovative immunoassay products, non-invasive saliva collection methods, and laboratory testing services.

Share article on social media or email:

Prevent Blindness Designates April as Women’s Eye Health and Safety Month to Educate Public on a Variety of Women’s Vision Issues


Prevent Blindness declares April as Women’s Eye Health and Safety Month to encourage women to make their vision a priority.

“We encourage women to be a model for good health by making their eyecare a priority today to ensure healthy vision for years to come,” said Kira Baldonado, Vice President of Public Health and Policy at Prevent Blindness.

Two out of every three people living with blindness or vision problems are women, according to the National Eye Institute. That’s why Prevent Blindness, the nation’s leading nonprofit eye health organization, has declared April as Women’s Eye Health and Safety Month. Because many of the effects of vision loss from eye disease can be lessened if detected and treated early, the group offers a variety of expert-reviewed free resources, including videos, fact sheets and shareable social media graphics on a range of eye health issues. Information on eye safety topics, including contact lenses, cosmetics and ultraviolet (UV) protection is also available.

For some, pregnancy brings an increase in hormones that may cause changes in vision. In most cases, these are temporary eye conditions that will return to normal after delivery. Those with pre-existing eye conditions, such as diabetes, high blood pressure, and glaucoma, should inform their eye doctor of their pregnancy to help monitor their health.

Women who are perimenopausal (nearing menopause) or already in menopause may also experience vision changes. Dry eye occurs at double the rate in postmenopausal women, according to the American Academy of Ophthalmology (AAO).

Women have a higher prevalence of many of the major vision problems, including:

  • Age-related Macular Degeneration
  • Cataract
  • Dry Eye
  • Glaucoma
  • Refractive Error
  • Thyroid Eye Disease

The AAO also states that women are more susceptible to autoimmune diseases than men, many of which affect vision, such as lupus and Sjögren’s syndrome.

As part of the Prevent Blindness Focus on Eye Health Expert Series, Janine Austin Clayton, M.D., FARVO, Associate Director for Research on Women’s Health and Director, Office of Research on Women’s Health at the National Institutes of Health (NIH), shares her thoughts on a variety of women’s eye health issues including equitable access to eyecare, addressing the impact of vision loss on mental health, and more in the new “Women’s Eye Health and Safety” episode.

In regards to eye safety, according to the Centers for Disease Control and Prevention (CDC), two-thirds of the 45 million people in the United States who wear contact lenses are women. Prevent Blindness reminds everyone that a prescription from a qualified eyecare professional is required to legally purchase contact lenses in this country, and to always wear contact lenses under the supervision of an eye doctor. Tips for safely caring for contact lenses may be found at: preventblindness.org/wearing-contact-lenses/

“Women lead incredibly busy and diverse lives- from running companies to running households. It is critical for women to take care of their own health needs, including eye health, to ensure they can be there for others,” said Kira Baldonado, Vice President of Public Health and Policy at Prevent Blindness. “We encourage women to be a model for good health by making their eyecare a priority today to ensure healthy vision for years to come.”

For more information on women’s eye health topics, including fact sheets on eye diseases and eye safety, please visit PreventBlindness.org. Prevent Blindness also offers a free listing of financial assistance services in English and Spanish at: preventblindness.org/vision-care-financial-assistance-information/.

About Prevent Blindness

Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at preventblindness.org, and follow us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

###

Share article on social media or email:

Using Proteomics to Build Next-Gen Diagnostic Solutions, Upcoming Webinar Hosted by Xtalks


Directly quantifying the expression of target proteins and their networks throughout all phases of precision oncology, from drug development through to patient selection, is critically important.

Personalized oncology aims to match each patient to a specific therapy based on the molecular characteristics of their tumor. Currently, tumor DNA is sequenced, and genomics reports are given to physicians to help select targeted therapies for patients. While this genome-centric approach to precision oncology has extended the lives of subsets of patients, many patients do not respond to the selected therapy, and many whose tumors initially respond have a high chance of recurrence with resistant disease. New approaches are required to capture complex clinical phenotypes and better match patients to efficacious therapies.

Most molecularly targeted therapies (e.g., kinase inhibitors, immune checkpoint inhibitors) do not directly target the cancer genome but rather target proteins in cancer cells or the tumor microenvironment. Neither DNA nor RNA profiles are reliable indicators of protein expression or activity levels. Thus, directly quantifying the expression of target proteins and their networks throughout all phases of precision oncology, from drug development through to patient selection, is critically important.

This webinar will discuss the added value of proteogenomics to the current genome-driven approach to precision oncology. The speaker will summarize the growing incorporation of targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry into: preclinical research; clinical trials and; clinical laboratories to support target discovery, pharmacodynamic and mechanism of action studies (e.g., PMID: 30385821, 34359745), correlative studies (e.g., PMID: 36259971) and the quantification of diagnostic proteins (e.g., PMID: 36388059). The establishment of proteomics represents an important component towards implementation of broader precision medicine efforts in oncology and beyond. (See also: PMID: 30487530 and PMID: 33798439.)

Register for this webinar to learn about the advantage of using proteomics to build next-gen diagnostic solutions for precision oncology.

Join Dr. Amanda Paulovich, MD, PhD, Professor and Aven Foundation Endowed Chair, Director, CLIA Targeted Proteomic Laboratory, Clinical Research Division, Fred Hutchinson Cancer Center, for the live webinar on Thursday, April 20, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Precision Oncology Approaches: Using Proteomics to Build Next-Gen Diagnostic Solutions.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

DiabetesSisters Board of Directors Announce Interim CEO


Michele Polz, Interim CEO

“Thank you to the Board for this tremendous honor and Anna for building a solid foundation. DiabetesSisters is on a growth trajectory as we expand our reach into communities nationwide, empowering women living with diabetes to take charge of their health and well-being.” – Michele Polz, Interim CEO

Anna Norton, MS, has announced her decision to step down as Chief Executive Officer of the organization, effective March 31, 2023. She will remain active in the health advocacy community.

The Board of Directors has named Michele Polz interim Chief Executive Officer effective March 31. Ms. Polz’s roots are deeply connected to DiabetesSisters, first as an industry partner responsible for its initial funding in 2009 and later joining the Board of Directors in 2016, serving as Chair of the Board from 2020-2021. She has driven the organization’s vision and mission toward its success.

Over the last eight years, the DiabetesSisters team led by Ms. Norton has worked collaboratively to elevate the organization into a vital resource for women living with diabetes. Highlights include:

  • building a Board of Directors to include the representation and interests of those with diabetes;
  • orchestrating virtual and in-person programming to reflect the needs of over half a million women through conferences, seminars, and online and printed resources in English, Spanish, Bengali, Gujarati, and Hindi, as well as launching a five-city outreach program to reflect the diabetes needs of African American, Hispanic/Latino and Indian population;
  • creating a membership program to include the needs of industry partners and DiabetesSisters, working with institutions of higher learning to drive research, and collaborating with other nonprofits to expand reach and knowledge of the intersection of diabetes, heart disease, and kidney disease;
  • aligning the organization with a long-term strategic growth map to meet the demands of the marketplace while securing the organization with financial footing to carry out its strategic plans; and
  • exploring new technologies with Digital Health & Artificial Intelligence partners.

Deborah Greenwood, Ph.D., RN, BC-ADM, CDCES, FADCES, DiabetesSisters’ Chair of the Board, said, “DiabetesSisters is grateful for Anna’s dedication and determination to flourish the organization. Her leadership has provided local, national, and international recognition as a leading diabetes-focused organization for women. The Board is confident that Ms. Polz’s experience and expertise will continue to elevate DiabetesSisters during this transition period. DiabetesSisters is searching for the next CEO to carry on the mission and drive DiabetesSisters into new strategic growth areas.”

Michele Polz, Interim CEO, said, “thank you to the Board for this tremendous honor and Anna for building a solid foundation. DiabetesSisters is on a growth trajectory as we expand our reach into communities nationwide, empowering women living with diabetes to take charge of their health and well-being. I look forward to working with the Board, DiabetesSisters community members, and industry partners to drive strategic growth and plan during this transition period.”

About DiabetesSisters:

A 501(c)(3) nonprofit, DiabetesSisters, is the only national organization focusing exclusively on women with diabetes. Our mission is to improve the health and quality of life of women living with and at risk of diabetes and to advocate on their behalf. DiabetesSisters has a 50,000+ member peer network that unites women with diabetes for support, education, and advocacy. Signature programs include monthly peer support meetings (PODS Meetups); the Welcoming Diversity, Elevating Voices Program; the annual Leadership Institute for volunteer peer support leaders; online expert articles, blog posts, and forums. For more information, visit diabetessisters.org.

Share article on social media or email:

Catalent Launches New Oral Developability Assessment and Manufacturing Solution to Advance Targeted Protein Degrader Programs


Targeted protein degraders have the potential to revolutionize new small molecule therapies, but if they are to be successful oral treatments, they require a rational approach to development and a comprehensive toolkit of proven technologies.

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the launch of the ProteoSuiteSM Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into clinical trials. These emerging therapeutic modalities are typically highly potent and present novel oral bioavailability challenges to formulators.

The new ProteoSuite Oral platform leverages Catalent’s successful 90-year track record of advancing thousands of complex molecules for oral drug development, including experience with multiple protein degrader programs, together with the development of custom TPD-specific assays and physiologically based pharmacokinetic (PBPK) and developability models. Customers using the service will benefit from the identification of those orally developable drug candidates with the greatest chance of success, and a development path to the clinic with consideration of the necessary advanced formulation technologies such as lipid-based delivery and amorphous solid dispersions, as well as manufacturing, specialty handling, and integrated clinical supply capabilities to accommodate these highly potent molecules.

Targeted protein degraders show significant promise in therapeutic areas such as oncology and beyond, but because of their complex structures, and physico-chemical properties, achieving satisfactory oral exposure can be challenging. They also present additional formulation and handling challenges.

“Targeted protein degraders have the potential to revolutionize new small molecule therapies, but if they are to be successful oral treatments, they require a rational approach to development and a comprehensive toolkit of proven technologies to address their ‘not so small’ characteristics and potency,” said Julien Meissonnier, Catalent’s Vice President and Chief Scientific Officer. “This new service provides customers with a logical and comprehensive development path, access to Catalent’s multi-center manufacturing capabilities designed to handle highly potent compounds, and its experience in scaling up and advancing successful products to market.”

Catalent’s network of early phase development sites includes facilities in St. Petersburg, Florida, San Diego, and Somerset, New Jersey, in the U.S., as well as Nottingham, U.K., and Beinheim, France. Development of targeted protein degraders at these sites will be supported by analytical, scale up and commercial sites with specific capabilities in handling potent drug products in Greenville, North Carolina, Kansas City, Missouri, Winchester, Kentucky, St. Petersburg, Beinheim, and Schorndorf and Eberbach in Germany.

About Catalent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

Explore how Innovations in Technology are Improving Life Sciences


News Image

An upcoming segment of Advancements with Ted Danson will discover how technology is being used to redefine continuous validation throughout the life sciences industry.

With a look at the rapid adoption of cloud technology, viewers will learn about the importance of validating cloud applications and why there is a need to update current toolsets and validation approaches.

Audiences will learn how developments in technology are providing continuous validation for the life science industry, creating efficiency throughout life cycle management. Spectators will see how xLM is using automation to remove mundane tasks and improve compliance and other services throughout the sector.

In addition, the show will explore how the technology offers cost efficient validation that saves time and delivers validated, real-time access to cloud technology.

“Validating cloud applications can be a daunting task – considering the frequency of patches, upgrades, and releases. We look forward to exploring how Valimation’s continuous validation paradigm is revolutionizing the mundane task of validation,” said Richard Lubin, senior producer for the Advancements series.

About Valimation:

xLM – Continuous Validation is a technology firm based in the Jacksonville, FL. Its managed service is governed by a cutting-edge Quality Management System built on ISO 9001:2015, 21 CFR Part 11, Annex 11 and GxPs. xLM is a subsidiary of ValiMation Inc., an established name in the GxP and validation-related consulting space serving big and small Life Sciences companies globally since 1996.

For more information, visit: http://www.continuousvalidation.com.

About Advancements and DMG Productions:

Advancements is an information-based educational television series that explores recent developments taking place across several industries and economies. Shining a light on important issues and topics impacting society today, the series features the cutting-edge improvements, state-of-the-art technologies, and innovative solutions responsible for shaping, molding, and transforming our world.

Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming for viewers and networks.

For more information, please visit http://www.AdvancementsTV.com or call 866-496-4065.

Share article on social media or email: